How hyaluronidase breaks down hyaluronic acid filler
What the enzyme does to crosslinked gel, why product characteristics change how much is needed, and what it also does to the patient's own tissue.
Hyaluronidase depolymerises hyaluronic acid by cleaving the glycosidic bonds in the chain. That single sentence covers the mechanism; almost everything clinically interesting is in the qualifications.
Crosslinking changes the target
Native hyaluronic acid is a long unbranched chain, cleared from tissue within a day or two. Filler hyaluronic acid is crosslinked — chains tied together into a three-dimensional network — which is what gives it persistence and mechanical behaviour.
The enzyme still cleaves the chains, but a densely crosslinked network presents fewer accessible sites and holds together after partial cleavage. The practical consequence is that products differ in how readily they dissolve: a soft, lightly crosslinked gel yields quickly, while a dense, highly crosslinked structural product may need repeated treatment.
Concentration and cohesivity contribute as well. A cohesive, high-concentration gel presents less surface area to the enzyme per unit volume than the same material dispersed.
Contact is the limiting factor
Hyaluronidase works where it physically reaches the gel. This is why the technique for emergency use differs so sharply from elective dissolution: the aim is to flood the affected territory so the enzyme reaches product distributed along a vessel, not to deposit a neat dose at one point.
The same reasoning explains repeat dosing. Enzyme has a short tissue half-life; a single administration acts briefly, and pulsed repetition maintains the concentration long enough to work through a resistant mass.
What else it degrades
The enzyme does not distinguish filler hyaluronic acid from the patient’s own. Treatment temporarily reduces native dermal hyaluronic acid in the treated area, and patients commonly report the region looking flatter or more lined than before for a period afterwards.
This resolves — native HA turns over quickly — but it should be part of the conversation before elective dissolution, because a patient expecting to return to their pre-filler appearance immediately will be alarmed.
Dose is clinical, not arithmetic
There is no reliable units-per-millilitre conversion. The variables — product, crosslinking, volume, time in situ, tissue plane, individual response — are too many. Published guidance describes titrating to effect and reassessing, both for elective dissolution over successive sessions and for emergency management within a single episode.
Allergy
True hypersensitivity is uncommon but described. Practices differ on skin testing; the case for omitting it in an emergency is straightforward, since the risk of untreated occlusion outweighs the risk of a reaction that can itself be managed.
